Abstract
Pruritus can be a debilitating symptom in patients with chronic cholestasis. Based on previous reports of its efficacy, we evaluated the impact of rifampin on the pruritus associated with primary biliary cirrhosis. Fourteen patients were included in a randomized, crossover study. After a 15-day washout period, subjects were followed for three weeks. During the first and third week, patients received 600 mg of rifampin or placebo; no treatment was administered during the second week. Pruritus was subjectively scored on a scale from 0 to 100. With rifampin, pruritus disappeared in 11 patients and partially improved in three; with placebo, only two had a partial response (P<0.001). Six patients with a prior poor or no response to cholestyramine improved with rifampin. No changes in biochemical tests or side effects were observed during this period. We conclude that short-term administration of rifampin relieves pruritus in primary biliary cirrhosis. When administered over a period of eight months in an open study, the relief of pruritus was maintained, while one individual developed an allergic reaction. Rifampin appears to be a safe drug in the management of the pruritus of primary biliary cirrhosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ghent C: Pruritus of cholestasis is related to effects of bile salts on the liver not the skin. Am J Gastroenterol 82:117–118, 1987
Carey J, Williams G: Relief of pruritus of jaundice with a bile acid sequesterin resin. JAMA 176:432–435, 1961
Thomas H, Sherlock S: Testosterone therapy for the pruritus of obstructive jaundice. Br Med J 2:1289–1291, 1952
Bloomer J, Boyer J: Phenobarbital effects in cholestatic liver disease. Ann Intern Med 82:310–317, 1975
Duncan J, Kennedy H, Triger D: Treatment of pruritus due to chronic obstructive liver disease. Br Med J 289:22, 1984
Lauterburg B, Pineda A, Burgstaler E: Treatment of pruritus of cholestasis by plasma perfusion through charcoal-coated glassbeads. Lancet 1:53–55, 1980
Garden J, Ostrow JD, Roenigk HH Jr: Pruritus in hepatic cholestasis. Pathogenesis and therapy. Arch Dermatol 121:1415–1420, 1985
Ghent C, Carruthers C: Treatment of pruritus in primary biliary cirrhosis with rifampicin. Gastroenterology 94:488–493, 1988
Bachs L, Pares A, Elena M, Piera C, Rodes J: Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 2:574–576, 1989
Scheuer PJ: Liver Biopsy Interpretation. Baltimore, Maryland, Williams and Wilkins, 1974
Girling G, Hitze K: Adverse reactions to rifampicin. Bull WHO 57:45–49, 1979
Grosset J, Leventis S: Adverse effects of Rifampin. Rev Infect Dis 5(3):S440-S446, 1983
Galeazi R, Lorenzini I: Rifampicin induced elevation of serum bile acid in man. Dig Dis Sci 25:102–112, 1980
McConell J, Powell Jackson P, Davis M: Use of liver function tests as predictor of rifampicin metabolism in cirrhosis. Q J Med 197:77–82, 1981
Girling D: Hepatitis and other adverse reactions to antituberculous chemotherapy. Bull Int Union Tuber 51:8–12, 1980
Rothwell D, Richmond D: Hepatorenal failure with self-initiated intermittent therapy with rifampin. Br Med J 2:481–482, 1974
Flynn C, Rainford D, Hope E: Acute renal failure and rifampicin: danger of unsuspected intermittent dosage. Br Med J 2:482, 1974
Winter R, Banks: Rifampicin induced light chain proteinuria and renal failure. Thorax 39:952–953, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Podesta, A., Lopez, P., Terg, R. et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Digest Dis Sci 36, 216–220 (1991). https://doi.org/10.1007/BF01300759
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01300759